JP7749186B2 - Fms様チロシンキナーゼ3リガンド(flt3l)ベースキメラタンパク質 - Google Patents

Fms様チロシンキナーゼ3リガンド(flt3l)ベースキメラタンパク質

Info

Publication number
JP7749186B2
JP7749186B2 JP2021558523A JP2021558523A JP7749186B2 JP 7749186 B2 JP7749186 B2 JP 7749186B2 JP 2021558523 A JP2021558523 A JP 2021558523A JP 2021558523 A JP2021558523 A JP 2021558523A JP 7749186 B2 JP7749186 B2 JP 7749186B2
Authority
JP
Japan
Prior art keywords
chimeric protein
ifnβ
mutation
seq
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021558523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527322A5 (cg-RX-API-DMAC7.html
JP2022527322A (ja
Inventor
クレイ,ニコライ
タヴァーニアー,ジャン
パリス,アレクサンダー ヴァン
Original Assignee
オリオニス バイオサイエンシズ,インコーポレイテッド
ブイアイビー ブイゼットダブリュー
ユニバーシテイト ヘント
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オリオニス バイオサイエンシズ,インコーポレイテッド, ブイアイビー ブイゼットダブリュー, ユニバーシテイト ヘント filed Critical オリオニス バイオサイエンシズ,インコーポレイテッド
Publication of JP2022527322A publication Critical patent/JP2022527322A/ja
Publication of JP2022527322A5 publication Critical patent/JP2022527322A5/ja
Priority to JP2025067565A priority Critical patent/JP7891720B2/ja
Application granted granted Critical
Publication of JP7749186B2 publication Critical patent/JP7749186B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2021558523A 2019-03-28 2020-03-27 Fms様チロシンキナーゼ3リガンド(flt3l)ベースキメラタンパク質 Active JP7749186B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025067565A JP7891720B2 (ja) 2019-03-28 2025-04-16 Fms様チロシンキナーゼ3リガンド(flt3l)ベースキメラタンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962825579P 2019-03-28 2019-03-28
US62/825,579 2019-03-28
PCT/US2020/025419 WO2020198659A1 (en) 2019-03-28 2020-03-27 Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025067565A Division JP7891720B2 (ja) 2019-03-28 2025-04-16 Fms様チロシンキナーゼ3リガンド(flt3l)ベースキメラタンパク質

Publications (3)

Publication Number Publication Date
JP2022527322A JP2022527322A (ja) 2022-06-01
JP2022527322A5 JP2022527322A5 (cg-RX-API-DMAC7.html) 2023-04-03
JP7749186B2 true JP7749186B2 (ja) 2025-10-06

Family

ID=72608957

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021558523A Active JP7749186B2 (ja) 2019-03-28 2020-03-27 Fms様チロシンキナーゼ3リガンド(flt3l)ベースキメラタンパク質
JP2025067565A Active JP7891720B2 (ja) 2019-03-28 2025-04-16 Fms様チロシンキナーゼ3リガンド(flt3l)ベースキメラタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025067565A Active JP7891720B2 (ja) 2019-03-28 2025-04-16 Fms様チロシンキナーゼ3リガンド(flt3l)ベースキメラタンパク質

Country Status (6)

Country Link
US (1) US20220185857A1 (cg-RX-API-DMAC7.html)
EP (1) EP3946409A4 (cg-RX-API-DMAC7.html)
JP (2) JP7749186B2 (cg-RX-API-DMAC7.html)
CN (1) CN113645988A (cg-RX-API-DMAC7.html)
CA (1) CA3133830A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020198659A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020198665A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Fibroblast activation protein binding agents and use thereof
CN114606227B (zh) * 2022-02-22 2024-03-08 复旦大学 高精度腺嘌呤碱基编辑器及其应用
AU2024341598A1 (en) * 2023-09-12 2026-04-23 Heligenics Inc. Engineered interferon-beta proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001504689A (ja) 1996-10-25 2001-04-10 ジー.ディー.サール アンド カンパニー 多機能性キメラ造血レセプターアゴニスト
JP2007515946A (ja) 2003-06-13 2007-06-21 オンコマックス アクイジション コーポレイション 抗腫瘍二元機能融合タンパク質の調製および適用
JP2019507762A (ja) 2016-03-07 2019-03-22 ブイアイビー ブイゼットダブリュー Cd20結合単一ドメイン抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294331B2 (en) * 1994-03-07 2007-11-13 Immunex Corporation Methods of using flt3-ligand in hematopoietic cell transplantation
US20020034517A1 (en) * 1995-10-04 2002-03-21 Kenneth Brasel Dendritic cell stimulatory factor
US6660257B1 (en) * 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
US6291661B1 (en) * 1998-07-02 2001-09-18 Immunex Corporation flt3-L mutants and method of use
US20050232931A1 (en) * 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
WO2013107791A1 (en) * 2012-01-20 2013-07-25 Vib Vzw Targeted mutant alpha-helical bundle cytokines
WO2015168474A1 (en) * 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
JP6898325B2 (ja) * 2015-12-08 2021-07-07 ユニバーシティ−インダストリー・ファンデーション・ヨンセイ・ユニバーシティ GM−CSF遺伝子;Flt3L−TRAIL融合遺伝子;TGF−βの発現を抑制するshRNA;およびHSP発現を抑制するshRNAを含む抗腫瘍組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001504689A (ja) 1996-10-25 2001-04-10 ジー.ディー.サール アンド カンパニー 多機能性キメラ造血レセプターアゴニスト
JP2007515946A (ja) 2003-06-13 2007-06-21 オンコマックス アクイジション コーポレイション 抗腫瘍二元機能融合タンパク質の調製および適用
JP2019507762A (ja) 2016-03-07 2019-03-22 ブイアイビー ブイゼットダブリュー Cd20結合単一ドメイン抗体

Also Published As

Publication number Publication date
US20220185857A1 (en) 2022-06-16
JP2025111546A (ja) 2025-07-30
WO2020198659A1 (en) 2020-10-01
CN113645988A (zh) 2021-11-12
JP7891720B2 (ja) 2026-07-17
EP3946409A1 (en) 2022-02-09
EP3946409A4 (en) 2023-06-21
JP2022527322A (ja) 2022-06-01
CA3133830A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
JP7729778B2 (ja) Fms様チロシンキナーゼ3(flt3)に対するキメラタンパク質およびキメラタンパク質複合体
EP3411398B1 (en) Targeted therapeutic agents and uses thereof
JP7620045B2 (ja) Tigit及びlightベースのキメラタンパク質
US12527843B2 (en) Immune-cell targeted bispecific chimeric proteins and uses thereof
JP2025111546A (ja) Fms様チロシンキナーゼ3リガンド(flt3l)ベースキメラタンパク質
US20220089668A1 (en) Targeted mutant interferon-beta and uses thereof
JP7660523B2 (ja) アルカリリン酸塩に基づいた癌治療
KR20190124247A (ko) Csf1r-기반 키메라 단백질
KR20230026983A (ko) 알파-엔올라아제 항체들을 포함하는 약물 접합체 및 그의 이용
JP2025121986A (ja) コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物
US11661455B2 (en) Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
HK40116401A (en) Targeted therapeutic agents and uses thereof
RU2792239C2 (ru) Химерные белки на основе csf1r
EP4717277A1 (en) Use of drug conjugate in treating tumor disease and method therefor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240909

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250416

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250819

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250911

R150 Certificate of patent or registration of utility model

Ref document number: 7749186

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150